M Nagamani1, C A Stuart. 1. Department of Obstetrics and Gynecology, University of Texas Medical Branch, Galveston 77555, USA.
Abstract
OBJECTIVE: Insulin is known to be mitogenic to a variety of cells in culture. The purpose of this study was to investigate the possible role of insulin in the growth and development of endometrial cancers. STUDY DESIGN: Specific binding and growth effects of insulin were studied in 5 different human endometrial cancer cell lines derived from cancers with different degrees of differentiation: HEC-1-A and HEC-1-B (from a moderately well-differentiated adenocarcinoma), RL95-2 (from a moderately well-differentiated adenosquamous carcinoma), KLE (from poorly differentiated carcinoma), and AN3 CA (from a metastatic undifferentiated endometrial carcinoma). The receptors were further characterized by competitive binding and chemical cross-linking studies. RESULTS: Binding studies with 125I-insulin revealed the presence of high-affinity binding sites for insulin on all the 5 cell lines. Binding of insulin was found to be highly specific. Competitive binding studies with 125I-insulin revealed that insulin was most effective in displacing the labeled hormone, whereas insulin-like growth factor-I and insulin-like growth factor-II competed for binding only at very high concentrations. Scatchard analysis of the binding data revealed that the association constant for the high-affinity binding sites ranged from 0.72 to 1.91 x 10(9) L/mol. Estrogen-receptor-negative cell lines HEC-1-A and HEC-1-B had the highest number of insulin receptors, whereas the estrogen-receptor-positive cell line RL95-2 had the least number of receptors. The effect of insulin on cell proliferation was studied by monitoring cell number and incorporating [3H]thymidine into deoxyribonucleic acid of the cells. Insulin stimulated cell growth of all the cell lines. CONCLUSIONS: The results of this study indicate the potential role of hyperinsulinemia in the growth and development of endometrial cancer.
OBJECTIVE:Insulin is known to be mitogenic to a variety of cells in culture. The purpose of this study was to investigate the possible role of insulin in the growth and development of endometrial cancers. STUDY DESIGN: Specific binding and growth effects of insulin were studied in 5 different humanendometrial cancer cell lines derived from cancers with different degrees of differentiation: HEC-1-A and HEC-1-B (from a moderately well-differentiated adenocarcinoma), RL95-2 (from a moderately well-differentiated adenosquamous carcinoma), KLE (from poorly differentiated carcinoma), and AN3 CA (from a metastatic undifferentiated endometrial carcinoma). The receptors were further characterized by competitive binding and chemical cross-linking studies. RESULTS: Binding studies with 125I-insulin revealed the presence of high-affinity binding sites for insulin on all the 5 cell lines. Binding of insulin was found to be highly specific. Competitive binding studies with 125I-insulin revealed that insulin was most effective in displacing the labeled hormone, whereas insulin-like growth factor-I and insulin-like growth factor-II competed for binding only at very high concentrations. Scatchard analysis of the binding data revealed that the association constant for the high-affinity binding sites ranged from 0.72 to 1.91 x 10(9) L/mol. Estrogen-receptor-negative cell lines HEC-1-A and HEC-1-B had the highest number of insulin receptors, whereas the estrogen-receptor-positive cell line RL95-2 had the least number of receptors. The effect of insulin on cell proliferation was studied by monitoring cell number and incorporating [3H]thymidine into deoxyribonucleic acid of the cells. Insulin stimulated cell growth of all the cell lines. CONCLUSIONS: The results of this study indicate the potential role of hyperinsulinemia in the growth and development of endometrial cancer.
Authors: Jennifer Prescott; Ying Bao; Akila N Viswanathan; Edward L Giovannucci; Susan E Hankinson; Immaculata De Vivo Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-05-23 Impact factor: 4.254
Authors: Marc J Gunter; Jennifer A Schaub; Xiaonan Xue; Neal D Freedman; Mia M Gaudet; Thomas E Rohan; Albert R Hollenbeck; Rashmi Sinha Journal: Int J Cancer Date: 2011-11-17 Impact factor: 7.396
Authors: Jason Y Y Wong; Gordon S Huggins; Marcella Debidda; Nikhil C Munshi; Immaculata De Vivo Journal: Gynecol Oncol Date: 2008-04-18 Impact factor: 5.482
Authors: Marc J Gunter; Donald R Hoover; Herbert Yu; Sylvia Wassertheil-Smoller; Joann E Manson; Jixin Li; Tiffany G Harris; Thomas E Rohan; Xiaonan Xue; Gloria Y F Ho; Mark H Einstein; Robert C Kaplan; Robert D Burk; Judith Wylie-Rosett; Michael N Pollak; Garnet Anderson; Barbara V Howard; Howard D Strickler Journal: Cancer Epidemiol Biomarkers Prev Date: 2008-04 Impact factor: 4.254
Authors: Christine M Friedenreich; Annie R Langley; Thomas P Speidel; David C W Lau; Kerry S Courneya; Ilona Csizmadi; Anthony M Magliocco; Yutaka Yasui; Linda S Cook Journal: Endocr Relat Cancer Date: 2012-11-09 Impact factor: 5.678